<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419665</url>
  </required_header>
  <id_info>
    <org_study_id>GP13-301</org_study_id>
    <secondary_id>2010-019522-13</secondary_id>
    <nct_id>NCT01419665</nct_id>
    <nct_alias>NCT03814785</nct_alias>
  </id_info>
  <brief_title>GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)</brief_title>
  <acronym>ASSIST_FL</acronym>
  <official_title>A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabTheraÂ® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate comparability of the ORR in patients with&#xD;
      previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive&#xD;
      MabThera-treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2011</start_date>
  <completion_date type="Actual">January 22, 2018</completion_date>
  <primary_completion_date type="Actual">July 10, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A subset of patients is switched from GP2013 to MabThera or continued with MabThera during the maintenance phase, for these patients the treatment is finished as an open labeled parallel arm study. The original treatment assignment is kept blinded.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>ORR is defined as the proportion of patients whose best overall disease response was either CR or PR during the combination treatment period based on blinded independent central radiology review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with progression free survival events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths</measure>
    <time_frame>3 years</time_frame>
    <description>OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, OS was censored at the date of last contact including survival follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)</measure>
    <time_frame>24 weeks, 3 years</time_frame>
    <description>number of participants with confirmed positive ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)</measure>
    <time_frame>day 63</time_frame>
    <description>C max&#xD;
For descriptive purposes only, no hypothesis testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)</measure>
    <time_frame>day 63</time_frame>
    <description>C through&#xD;
For descriptive purposes only, no hypothesis testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- Chemotherapy</measure>
    <time_frame>21 days</time_frame>
    <description>AUEC (0-21d)&#xD;
For descriptive purposes only, no hypothesis testing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">629</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>GP2013</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type: Biological/Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type: Biological/Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GP2013</intervention_name>
    <description>Type: Biological/Vaccine</description>
    <arm_group_label>GP2013</arm_group_label>
    <other_name>no brand name available</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Type: Biological/Vaccine</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>MabThera(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with previously untreated advanced stage, CD20-positive FL&#xD;
&#xD;
          -  Patient with ECOG performance status 0, 1 or 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with Grade 3b (aggressive) FL or any histology other than FL grade 1, 2 or 3a&#xD;
&#xD;
          -  Patient who has previously received any prior therapy for lymphoma&#xD;
&#xD;
          -  Patient with evidence of any uncontrolled, active infection (viral, bacterial or&#xD;
             fungal).&#xD;
&#xD;
          -  Patient with any malignancy within 5 years prior to date of randomization, with the&#xD;
             exception of adequately treated in situ carcinoma of the cervix uteri, basal or&#xD;
             squamous cell carcinoma or non-melanomatous skin cancer.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ballarat</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Epping</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Footscray</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Wodonga</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Botucatu</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Florianopolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Jau</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Passo Fundo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Santo Andre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Sorocaba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Monteria</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ioannina</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>GyÃ¶r</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>India</name>
      <address>
        <city>Amritsar</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Aurangabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigtive site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Nashik</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Surat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Komaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ogaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Invstigative site</name>
      <address>
        <city>Omura</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Tachikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Åtake</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Alor Setar</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ampang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>George Town</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ipoh</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Klang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kuching</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Melaka</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Subang Jaya</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Schiedam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Brzozow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Chorzow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Rostov-on -Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Eastbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative site</name>
      <address>
        <city>Worthing</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <results_first_submitted>March 5, 2019</results_first_submitted>
  <results_first_submitted_qc>April 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2021</results_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Biosimilar</keyword>
  <keyword>GP13-301</keyword>
  <keyword>rituximab</keyword>
  <keyword>Antibodies</keyword>
  <keyword>CD20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 629 patients were randomized at 159 centers in 26 countries, 314 patients to GP2013 (312 patients treated) and 315 to MabThera. Of those 314 patients in the GP2013 group, 2 patients were randomized by error and discontinued before any treatment with GP2013. The number of patients in both treatment groups remained similar.</recruitment_details>
      <pre_assignment_details>full analysis set participants : GP2013 312 MabThera 315 safety set participants : GP2013 312 MabThera 315 per protocol set participants: GP2013 310 MabThera 312 pharmacokinetic analysis set 1 : GP2013 119 MabThera 120 immunogenicity analysis set: GP2013 275 MabThera 287 pharmacodynamic analysis set : GP2013 24 MabThera 24</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GP2013</title>
          <description>Experimental Type: Biological/Vaccine</description>
        </group>
        <group group_id="P2">
          <title>Rituximab</title>
          <description>Comparator Type: Biological/Vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Combination Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
                <participants group_id="P2" count="315"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Treatment and/or Follow up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>switch to open label</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>full analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>GP2013</title>
          <description>Experimental Type: Biological/Vaccine</description>
        </group>
        <group group_id="B2">
          <title>Rituximab</title>
          <description>Comparator Type: Biological/Vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="312"/>
            <count group_id="B2" value="315"/>
            <count group_id="B3" value="627"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="11.86"/>
                    <measurement group_id="B2" value="56.4" spread="11.72"/>
                    <measurement group_id="B3" value="56.9" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic / Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian (Indian Subcontinent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown / missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR is defined as the proportion of patients whose best overall disease response was either CR or PR during the combination treatment period based on blinded independent central radiology review.</description>
        <time_frame>24 weeks</time_frame>
        <population>per protocol set, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR is defined as the proportion of patients whose best overall disease response was either CR or PR during the combination treatment period based on blinded independent central radiology review.</description>
          <population>per protocol set, participants with measure</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" lower_limit="83.59" upper_limit="90.15"/>
                    <measurement group_id="O2" value="87.5" lower_limit="84.04" upper_limit="90.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The equivalence margin of + or - 12% was determined considering the variability of the point estimate of the add-on effect by taking a value lower than the lower boundary of the 95% CI for Rituximab+chemotherapy versus chemotherapy obtained from historical data.</non_inferiority_desc>
            <param_type>difference in overall response rate</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.94</ci_lower_limit>
            <ci_upper_limit>5.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period</title>
        <time_frame>24 weeks</time_frame>
        <population>per protocol set, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period</title>
          <population>per protocol set, participants with measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period</title>
        <time_frame>24 weeks</time_frame>
        <population>per protocol set, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period</title>
          <population>per protocol set, participants with measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization</title>
        <description>Number of participants with progression free survival events</description>
        <time_frame>3 years</time_frame>
        <population>per protocol set, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization</title>
          <description>Number of participants with progression free survival events</description>
          <population>per protocol set, participants with measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>descriptive purposes, not powered for hypothesis testing</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths</title>
        <description>OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, OS was censored at the date of last contact including survival follow-up.</description>
        <time_frame>3 years</time_frame>
        <population>per protocol set, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths</title>
          <description>OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, OS was censored at the date of last contact including survival follow-up.</description>
          <population>per protocol set, participants with measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>descriptive purposes, not powered for hypothesis testing</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)</title>
        <description>number of participants with confirmed positive ADA</description>
        <time_frame>24 weeks, 3 years</time_frame>
        <population>immunogenicity set, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)</title>
          <description>number of participants with confirmed positive ADA</description>
          <population>immunogenicity set, participants with measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>end of treatment combination phase (24 weeks)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                    <count group_id="O2" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>end of treatment manintenance phase (3 years)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)</title>
        <description>C max&#xD;
For descriptive purposes only, no hypothesis testing</description>
        <time_frame>day 63</time_frame>
        <population>pharmacokinetic analysis set 1, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)</title>
          <description>C max&#xD;
For descriptive purposes only, no hypothesis testing</description>
          <population>pharmacokinetic analysis set 1, participants with measure</population>
          <units>microg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.59" spread="41.09"/>
                    <measurement group_id="O2" value="331.93" spread="35.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)</title>
        <description>C through&#xD;
For descriptive purposes only, no hypothesis testing</description>
        <time_frame>day 63</time_frame>
        <population>pharmacokinetic analysis set 1, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)</title>
          <description>C through&#xD;
For descriptive purposes only, no hypothesis testing</description>
          <population>pharmacokinetic analysis set 1, participants with measure</population>
          <units>microg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.42" spread="47.593"/>
                    <measurement group_id="O2" value="82.13" spread="61.526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- Chemotherapy</title>
        <description>AUEC (0-21d)&#xD;
For descriptive purposes only, no hypothesis testing</description>
        <time_frame>21 days</time_frame>
        <population>Pharmnacodynamic analysis set, participants with measure</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- Chemotherapy</title>
          <description>AUEC (0-21d)&#xD;
For descriptive purposes only, no hypothesis testing</description>
          <population>Pharmnacodynamic analysis set, participants with measure</population>
          <units>%*day</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1790" spread="23.5"/>
                    <measurement group_id="O2" value="1910" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>All Collected Deaths</title>
        <description>On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 30 months (treatment duration ranged from 90 to 782 days) Deaths post treatment survival follow up were collected after the on- treatment period, up to 3 years.</description>
        <time_frame>30 months, 3 years</time_frame>
        <population>clinical data base population - treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>GP2013</title>
            <description>Experimental Type: Biological/Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Rituximab</title>
            <description>Comparator Type: Biological/Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>All Collected Deaths</title>
          <description>On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 30 months (treatment duration ranged from 90 to 782 days) Deaths post treatment survival follow up were collected after the on- treatment period, up to 3 years.</description>
          <population>clinical data base population - treated patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>on treatment death</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>on treatment deaths maintenance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>all deaths</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On treatment AE, SAE and deaths were collected from the start of treatment up to 30/90 days after study drug discontinuation (30 days for combination phase and 90 for maintenance/open label phase), for a maximum duration of 30 months (treatment duration ranged from 90 to 782 days)</time_frame>
      <desc>Safety follow-up (treatment emergent AE/SAEs): after discontinuation of study treatment, all subjects were followed for safety for 30 days for combination phase and 90 for maintenance/open label phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combination GP2013+CVP</title>
          <description>Combination GP2013+CVP</description>
        </group>
        <group group_id="E2">
          <title>Combination MabThera+CVP</title>
          <description>Combination MabThera+CVP</description>
        </group>
        <group group_id="E3">
          <title>Maintenance GP2013</title>
          <description>Maintenance GP2013</description>
        </group>
        <group group_id="E4">
          <title>Maintenance MabThera</title>
          <description>Maintenance MabThera</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Polycystic liver disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Coagulation test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Meningeal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Laryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="255" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="144" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="315"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="254"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Hexal AG / Novartis Pharmaceuticals</organization>
      <phone>+41613241111</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

